Length of Diagnostic Delay in Patients with Non-small-cell Lung Cancer

被引:0
作者
Valdes, Solangel [1 ]
Garcia, Eberto [1 ]
Perez, Hayvin [1 ]
Hernandez, Marisela [1 ]
机构
[1] Hosp Neumol Benef Jurid, Havana, Cuba
关键词
Lung cancer; non-small-cell lung carcinoma; diagnosis; delivery of health care; SYMPTOMS;
D O I
暂无
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Introduction Despite advances in diagnostic techniques and treatment, lung cancer is the leading cause of cancer death worldwide and in Cuba. Prompt initiation of cancer therapy depends on rapid diagnostic confirmation; however, most patients are diagnosed at an advanced stage. In the Cuban health system, primary, secondary and tertiary levels of care are interrelated; patients may seek care at any level or may be referred from one to another. Lung cancer diagnoses are confirmed at the tertiary level. Objective Determine the length of diagnostic delay in patients diagnosed with non-small-cell lung cancer (NSCLC) at a tertiary care facility in Havana, Cuba, as well as mean diagnostic delay attributable to the patient and to the health system by level of care. Methods A descriptive observational study of 96 patients with a cytologically and/or histologically confirmed diagnosis of non-small-cell lung cancer was conducted in 2005-2007. Patients initially sought care for disease symptoms at primary, secondary or tertiary levels in the Cuban public health system, but diagnosis of all patients was confirmed at a specialized tertiary care facility. Total diagnostic delay was calculated as the time elapsed from onset of symptoms to confirmation of NSCLC diagnosis. Variables also included diagnostic delay attributable to the patient and diagnostic delay attributable to the health system by level of care. Data were arranged in tables and analyzed by absolute value, percentage, mean, and standard deviation. Results Of the 96 patients studied, 69% were male, and 54% were aged 50-69 years. Fifty-five percent of patients sought medical care within 15 days of onset of symptoms, 21% within 16-30 days, and 3% waited >90 days. Mean diagnostic delay attributable to the patient was 18.19 +/- 3.45 days while mean diagnostic delay attributable to the health system was 61.63 +/- 18.50 days, and overall diagnostic delay was 73.13 +/- 17.53 days. For the 71% of patients seen in primary care, mean diagnostic delay was 29.51 +/- 4.53 days; for the 45% seen exclusively or additionally at the secondary level, mean diagnostic delay was 24.45 +/- 7.31 days. Upon admission at the tertiary care level, mean diagnostic confirmation delay was 18.23 +/- 3.68 days. Conclusions Diagnostic delay of lung cancer patients in this study was prolonged. Appropriate strategies are needed for reducing this delay.
引用
收藏
页码:29 / 32
页数:4
相关论文
共 50 条
  • [41] The difficult choice of chemotherapy in patients with unresectable non-small-cell lung cancer
    M. Tamburini
    G. Buccheri
    C. Brunelli
    D. Ferrigno
    Supportive Care in Cancer, 2000, 8 : 223 - 228
  • [42] Treatment and outcomes of non-small-cell lung cancer patients with high comorbidity
    Rios, Jorge
    Gosain, Rahul
    Goulart, Bernardo H. L.
    Huang, Bin
    Oechsli, Margaret N.
    McDowell, Jaclyn K.
    Chen, Quan
    Tucker, Thomas
    Kloecker, Goetz H.
    CANCER MANAGEMENT AND RESEARCH, 2018, 10 : 167 - 175
  • [43] The Introduction of Systematic Genomic Testing for Patients with Non-Small-Cell Lung Cancer
    Cardarella, Stephanie
    Ortiz, Taylor M.
    Joshi, Victoria A.
    Butaney, Mohit
    Jackman, David M.
    Kwiatkowski, David J.
    Yeap, Beow Y.
    Jaenne, Pasi A.
    Lindeman, Neal I.
    Johnson, Bruce E.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (12) : 1767 - 1774
  • [44] Bayesian pharmacokinetic estimation of vinorelbine in non-small-cell lung cancer patients
    Sabot, C
    Marquet, P
    Debord, J
    Carpentier, N
    Merle, L
    Lachâtre, G
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 54 (02) : 171 - 175
  • [45] Sleeve lobectomy for patients with non-small-cell lung cancer: a simplified approach
    Konstantinou, Marios
    Potaris, Konstantinos
    Sakellaridis, Timothy
    Chamalakis, George
    EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2009, 36 (06) : 1045 - 1049
  • [46] Plasma microRNAs as potential biomarkers for non-small-cell lung cancer
    Shen, Jun
    Todd, Nevins W.
    Zhang, Howard
    Yu, Lei
    Lingxiao, Xing
    Mei, Yuping
    Guarnera, Maria
    Liao, Jipei
    Chou, Amy
    Lu, Changwan Larry
    Jiang, Zhengran
    Fang, HongBin
    Katz, Ruth L.
    Jiang, Feng
    LABORATORY INVESTIGATION, 2011, 91 (04) : 579 - 587
  • [47] Application of proteomics in non-small-cell lung cancer
    Cho, William C. S.
    EXPERT REVIEW OF PROTEOMICS, 2016, 13 (01) : 1 - 4
  • [48] Molecular pathology of non-small-cell lung cancer
    Breuer, RHJ
    Postmus, PE
    Smit, EF
    RESPIRATION, 2005, 72 (03) : 313 - 330
  • [49] Anthropometric measurements in non-small-cell lung cancer
    Domenico Ferrigno
    Supportive Care in Cancer, 2002, 10 : 440 - 440
  • [50] Vaccination therapy for non-small-cell lung cancer
    Cuppens, Kristof
    Vansteenkiste, Johan
    CURRENT OPINION IN ONCOLOGY, 2014, 26 (02) : 165 - 170